Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Plus Bevacizumab Biosimilar With or Without HAIC for Advanced Hepatocellular Carcinoma (TASK-03): a Multicenter, Randomized, Phase 2 Study

NCT06860490 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06860490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06860490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Plus Bevacizumab Biosimilar With or Without HAIC for Advanced Hepatocellular Carcinoma (TASK-03): a Multicenter, Randomized, Phase 2 Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2025
Completion date
March 10, 2028
Enrollment
164 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)